

# People

## Appointments

### Reliant Pharmaceuticals appoints new Chairman and CEO

Reliant Pharmaceuticals (<http://www.reliantrx.com>) have appointed Ernest Mario as Chairman and Chief Executive Officer. Mario brings over 35 years of industry experience to the New Jersey-based company.

Mario's career began in 1966 as a pharmaceutical researcher at Strassenburgh Laboratories in Rochester; he then went on to hold various management positions with SmithKline and Squibb and subsequently served as Chief Executive and Deputy Chairman of Glaxo. In 1993, Mario joined Alza Corporation as CEO where he consummated one of the largest mergers in pharmaceutical history. Mario founded Apothogen, which subsequently merged with IntraBiotics.

Joseph Krivulka, President and co-founder of Reliant, commented: 'As CEO of Glaxo, Mario turned the company into the second largest global pharmaceutical company at the time. He later transformed Alza Corporation from a drug delivery platform company into a thriving emerging pharmaceutical company... I believe with Ernie's help, Reliant is poised to accelerate its evolution into a leading global pharmaceutical company.'

'Reliant represents an excellent platform from which to build a global pharmaceutical company and I am very excited to be joining such a talented team.'

### Philip M. Brown appointed VP Development at Lexicon

Philip M. Brown has been appointed Vice President of Development at Lexicon Genetics (<http://www.lexgen.com>), where he will be responsible for directing clinical development of drugs arising from Lexicon's drug discovery programs.

Brown brings more than a decade of experience in managing medical affairs, drug safety and clinical programs, across multiple therapeutic areas in the pharmaceutical industry. During his career, Brown has advanced compounds from preclinical studies into clinical

development... and has conducted over 200 Phase I studies as an investigator.

Arthur T. Sands, President and Chief Executive Officer at Lexicon, said: 'Brown's broad medical expertise in clinical development is particularly valuable given that Lexicon's unique approach generates clinical opportunities in cardiovascular disease, diabetes, obesity, cancer, inflammation and neuropsychiatric disorders.' He added, 'His significant experience in cardiovascular indications will also aid in accelerating some of Lexicon's most advanced programs in atherosclerosis and metabolic disease.'

Most recently, Brown served as VP, Clinical Development at Texas Biotechnology Corporation, prior to which he served as Associate VP, Medical Affairs at Pharmaceutical Research Associates.

Lexicon Genetics is a biopharmaceutical company focussed on the discovery of breakthrough treatments for human disease, and is using gene knockout technology to systematically discover the physiological functions and pharmaceutical use of genes.

### George Poste to head Arizona Biodesign Institute

George Poste has been named Director of the Arizona Biodesign Institute (<http://www.azbio.org>), Arizona State University's (ASU: <http://www.asu.edu>) new biodesign and biotechnology enterprise.

At present, Poste is Chief Executive of Health Technology Networks, a consulting group specializing in the application of genomics and computing in healthcare. From 1992–1999 he was President for R&D and Chief Science and Technology Officer at SmithKlineBeecham.

ASU President Michael Crow announced Poste's appointment on 29 April 2003 at a ceremony marking the institute's first state-of-the-art research facility, which is under construction on the university's main campus. He said, 'George Poste is one of the leading scientists in the world and there is no better person to lead Arizona Biodesign Institute (AzBio) into a world-class biodesign research center...' He continued, 'One of our most immediate goals at ASU is to build research facilities that will attract leading researchers from across the country and around the world.'

AzBio will house a core of ASU's elite, cutting-edge researchers, both those already at the university and those who will be recruited in the future. It draws together research efforts in biotechnology, information technology and nanotechnology to improve human health and quality of life through multidisciplinary research.

On his appointment, Poste said, 'It's my goal that AzBio will pioneer new approaches in both research and teaching.'

### Hassan not to join Pfizer: elected CEO of Schering-Plough

Fred Hassan, former Chairman and Chief Executive Officer of Pharmacia Corporation (<http://www.pharmacia.com>) announced that he will not be joining Pfizer (<http://www.pfizer.com>) as Vice Chairman and a member of the company's Board of Directors, when the companies merge. Hank McKinnell, Chairman and CEO of Pfizer, said: 'With the imminent closure of the merger, we've reached a natural transition point. Fred made a commitment to see this merger through, and the merger integration team has enabled us to prepare all of our plans for a successful integration.'

Hassan has, however, been elected President and CEO of Schering-Plough (<http://www.schering-plough.com>) by the Board of Directors. Richard de J. Osbourne, Director of Schering-Plough and Chairman of the Board, said: 'Fred Hassan is a proven leader, with the experience, business acumen and organizational skills to fully realize the potential of this great organization and its people.'

Prior to joining Schering-Plough, Hassan was Chairman and CEO of Pharmacia. He joined the former Pharmacia & Upjohn in May 1997 as CEO and was elected to the Board of Directors. Previous to this, he was Executive Vice President of Wyeth.

On this appointment, Hassan said, 'Schering-Plough is a company with a proud heritage. I believe in its long-term future. While there are significant challenges, my goal will be to deal with the urgent issues and establish strategies for growth.'

Hassan succeeds Richard Jay Kogan, Schering-Plough's former CEO and President, who announced his intention to retire in November 2002.

People was written by  
*Joanne Clough*